Kalaris Therapeutics, Inc. (KLRS) research
Kalaris Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.12
- As of
Kalaris Therapeutics, Inc. (KLRS): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
As of . Source: SEC EDGAR filings for KLRS. Method and limitations.
Share the KLRS intelligence card
See KLRS live in the terminal
Track KLRS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live KLRS terminal, freeActive signals for KLRS
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +126% to KLRS (2026Q2)
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in KLRS
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +126% to KLRS (2026Q2)
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in KLRS
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +126% to KLRS (2026Q2)
FREE, NO ACCOUNT
Every signal on KLRS, as it fires
You are seeing 5 of 11 signals recorded on KLRS since 2026-05-17.
The five above landed across 2 days. The other 6 were recorded on 2 other days. 8 of the 11 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KLRS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 482929106 · 2026Q2 | $608K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 482929106 · 2026Q2 | $390K | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 482929106 · 2026Q2 | $97K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KLRS
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
KLRS against its peers
KLRS's return on equity of -55.1% ranks in the 71st percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-04-30.
| Metric | KLRS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 16.8M | n/a | 11 |
| Operating margin | n/a | -152.0% | n/a | 10 |
| Net margin | n/a | -134.4% | n/a | 10 |
| Return on equity | -55.1% | -75.4% | 71 | 18 |
Peers (20): OSTX, FBIO, RNXT, ACET, PTHS, GANX, MAIA, VRCA, PMVP, ACRV, CSBR, ALDX, CNTB, TENX, NTRB, ATHE, ATRA, CING, ICCC, NRXS. Left out: TELO (no annual filing), BSEM (no annual filing), RLFTY (no annual filing), OKYO (period gap), APLM (period gap). Fiscal periods ending between 2025-06-30 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (KLRS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more KLRS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KLRSand get the insider, 13F, options, and confluence read in one view.